Stabilizing action of disodium cromoglycate on erythrocyte membrane.

Kuriyama, Kiyoshi; Okuno, Tadashi

doi:10.1248/bpb1978.4.779

Cited by 10 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the compound was effective on heat-induced hemolysis. Similar findings with DSCG were reported previously [15][16][17][18], suggesting that KP-136 maintains the conformation of the membrane lipid layer, exerting a DSCG-like membrane stabilizing activity, and the parallel experiments with these agents indicated that KP-136 is more potent than DSCG. However, these inhibitory effects on hemolysis were markedly reduced when erythrocytes were modified by TNBS which is known to bind with protein at the site of the c-amino group [19].…”

Section: Discussionsupporting

confidence: 89%

The protective effect of a new antiallergic agent, KP-136 on mast cell activation: A comparison with disodium cromoglycate

et al. 1988

View full text Add to dashboard Cite

The protective effects on mast cell activation were compared between a new antiallergic agent, KP-136 and disodium cromoglycate (DSCG), both of which inhibited the immunological degranulation of rat peritoneal mast cells. The IC50 was 0.03 micrograms/ml for KP-136 and 4.7 micrograms/ml for DSCG. KP-136 predominantly acted on the early stage of mast cell activation processes and inhibited the immunological increase in 45Ca uptake. KP-136 also inhibited A23187- and heat-induced degranulation and heat-induced hemolysis. In addition, KP-136 was effective on phospholipase A2-induced degranulation, although the compound did not directly affect the enzyme activity. In all tests for comparison, KP-136 and DSCG had similar profiles of action and the parallel experiments indicated that KP-136 was a more potent inhibitor of mast cell activation than DSCG, having a DSCG-like membrane stabilizing activity.

show abstract

Section: Discussionsupporting

confidence: 89%

The protective effect of a new antiallergic agent, KP-136 on mast cell activation: A comparison with disodium cromoglycate

et al. 1988

View full text Add to dashboard Cite

show abstract

“…In our experiments, the in vitro antisickling activity could be related to the blockade of calcium uptake due to calcium ion affinity for the drug ( Mazurek et al , 1980 ) and to stabilization of erythrocytes membranes similar to mast cells ( Foreman et al , 1981 ). This hypothesis is supported by Kuriyama & Okuno (1981) who showed that, in vitro , cromolyn sodium interacted with membrane lipids to stabilize rat erythrocytes and prevent haemolysis.…”

Section: Resultsmentioning

confidence: 68%

In vitro antisickling activity of cromolyn sodium

et al. 1998

View full text Add to dashboard Cite

Summary.The improvement in sickle cell disease (SCD) children receiving cromolyn sodium therapy prompted us to investigate its antisickling activity in vitro. The number of sickle cells was determined in deoxygenated blood samples from 15 children with severe SCD. At the eight concentrations tested, cromolyn sodium exhibited a significantly higher activity than pentoxifylline, the standard compound.Therefore cromolyn sodium would appear to be an interesting candidate for SCD therapy and deserves further in vivo investigations.Keywords: cromolyn sodium, antisickling activity, corpuscular indices.New approaches have been recently proposed for the treatment of SCD such as bone marrow transplantation or HbF synthesis modulation . Ancillary treatments aimed at the correction of secondary erythrocytic or rheological abnormalities also deserve renewed interest.At our centre, allergy had been previously diagnosed in 43% of SCD children. Treatment by allergen eviction and anti-allergic drugs such as cromolyn sodium was followed by a dramatic reduction of vaso-occlusive crises and of recurrent airway infections in some children (Toppet et al, 1993). Therefore we initiated an in vitro study of the possible effect of cromolyn sodium on sickling using as standard pentoxifylline whose antisickling activity, mediated by calcium L channels blockade, is well established (Ellory et al, 1994). MATERIALS AND METHODSBlood collection. Samples from 15 African children with severe SCD were collected. All the patients except two had a previous history of multiple recurrent vaso-occlusive crises. Seven of them were on hydroxyurea therapy at time of the study.The Hospital Ethics Committee approved the study protocol. Oral informed consent was obtained from patients and their legal guardians. Erythrocytes preparation. 5 ml of venous blood drawn in EDTA-rinsed tubes were processed within 2 h of collection. The red cells were washed three times in a phosphatebuffered saline (PBS, pH 7·40) and suspended in twice their volume of PBS.Drugs and control solutions. Stock-solutions of pentoxifylline (3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione, Hoechst Roussel, Bruxelles, Belgium) and of cromolyn sodium (5,5 0 -[(hydroxy-1,3-propanediyl)bis-(oxy)[bis] 4-oxo-4H-1-benzopyran-2-carboxylic acid, disodium salt], Sigma Chemie, Bornem, Belgium) were prepared in PBS and kept at 4ЊC. PBS was used as control.Deoxygenating device. The apparatus included a gas tank, a 250 ml glass flask half-filled with water, a 10 ml glass tube, a flexible duct and a water bath maintained at 37ЊC. All the containers were stoppered with their upper part allowing inlet and outlet of the gas (5% CO 2 in N 2 ) which was prehumidified by bubbling in the flask. After incubation for 60 min, 150 ml of the erythrocytes suspension to which had been added 150 ml of the tested drug solution, were transferred into the tube and the humidified gas was bubbled in the preparation for 30 min at a constant flow rate of 3 ml/ min. The lower part of the flask and the tube were im...

show abstract

“…5). A previous report from our laboratory demonstrated for the first time that DSCG exhibits a potent stabilizing activity on erythrocyte membranes [30]. A previous report from our laboratory demonstrated for the first time that DSCG exhibits a potent stabilizing activity on erythrocyte membranes [30].…”

Section: Figurementioning

confidence: 74%

“…However, its mode of action in asthmatics remains unclear, since the effects of DSCG on exericise [15,25,26]-, SO2 [15]-or histamine [7,15,27]-induced asthma and the alleviation of airway hyperreactivity can not be fully explained by inhibition of IgE-mediated release of chemical mediators. Several attempts have been made to relate the clinical efficacy of DSCG [24,[27][28][29][30][31] to inhibitory actions on ~adrenoceptor [27] and irritant receptors [28] as well as to an inhibitory effect on the bronchial smooth muscle contraction induced by pharmacological stimuli [29], but no previous report is available on the inhibitory effect of DSCG on rat type III allergic footpad swelling as demonstrated in this paper. Our data threw new light on the mode of action of DSCG, because the type III allergic reaction is closely associated with the late asthmatic reaction in man [32,33] and with viral or bacterial infections which also promote the clinically important symptoms of hyperreactivity [12,13].…”

Section: Figurementioning

confidence: 99%

An antiallergic activity of disodium cromoglycate unrelated to mast cell activation

et al. 1986

Self Cite

View full text Add to dashboard Cite

The pharmacological effects of disodium cromoglycate (DSCG) were studied in rats during the development of reactions to various allergens or carrageenin. DSCG (10 mg/kg and 100 mg/kg, i.v.) showed pronounced inhibitory effects on type I and type III (passive Arthus) allergic reactions. An immunological degranulation of mast cells and a significant decrease in tissue histamine content were observed in type I allergic reactions but not in type III allergic reactions characterized by an apparent infiltration of neutrophils. An antihistaminic agent, promethazine (1 mg/kg, i.v.) was effective only against type I allergic reactions and totally ineffective against type III allergic reactions. Thus, the results obtained above strongly suggest that DSCG exhibits at least two mechanisms of antiallergic action; one is related to mediator release from mast cells and the other is unrelated to mast cell activation.

show abstract

Stabilizing action of disodium cromoglycate on erythrocyte membrane.

Cited by 10 publications

References 14 publications

The protective effect of a new antiallergic agent, KP-136 on mast cell activation: A comparison with disodium cromoglycate

The protective effect of a new antiallergic agent, KP-136 on mast cell activation: A comparison with disodium cromoglycate

In vitro antisickling activity of cromolyn sodium

An antiallergic activity of disodium cromoglycate unrelated to mast cell activation

Contact Info

Product

Resources

About